Access to diphtheria antitoxin for therapy and diagnostics.

Area of Science:

• Medical Microbiology
• Immunology
• Public Health

Background:

• Diphtheria antitoxin (DAT) is a critical equine immunoglobulin preparation essential for treating diphtheria and for diagnostic testing.
• The World Health Organization designates DAT as an Essential Medicine, emphasizing its importance in global health systems.
• Despite its importance, DAT faces significant supply chain challenges, including production discontinuations and high manufacturing costs.

Purpose of the Study:

• To highlight the critical role of diphtheria antitoxin (DAT) in both therapeutic and diagnostic applications for diphtheria.
• To identify the primary reasons for the global scarcity and unavailability of DAT.
• To advocate for improved strategies to ensure DAT availability and explore alternative solutions.

Main Methods:

• Literature review and analysis of global supply chain issues related to diphtheria antitoxin.
• Examination of the role of DAT in diphtheria diagnostics and treatment protocols.
• Assessment of the economic and regulatory factors impacting DAT production and availability.

Main Results:

• Diphtheria antitoxin (DAT) is frequently unavailable globally due to production issues, economic non-viability, and stringent regulatory requirements.
• Diagnostic laboratories, particularly in the European Union, experience persistent difficulties in sourcing DAT for essential toxigenicity testing.
• The overall global access to DAT for both therapeutic and diagnostic purposes is deemed insufficient to meet demand.

Conclusions:

• Urgent improvements in the current supply of diphtheria antitoxin (DAT) are necessary.
• Accelerated research and development of alternatives, such as monoclonal antibodies for therapy and molecular methods for diagnostics, are crucial.
• Establishing a centralized stockpile and maintaining an inventory of DAT availability across European Union countries is recommended.